Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci.

Clyde MA, Palmieri Weber R, Iversen ES, Poole EM, Doherty JA, Goodman MT, Ness RB, Risch HA, Rossing MA, Terry KL, Wentzensen N, Whittemore AS, Anton-Culver H, Bandera EV, Berchuck A, Carney ME, Cramer DW, Cunningham JM, Cushing-Haugen KL, Edwards RP, Fridley BL, Goode EL, Lurie G, McGuire V, Modugno F, Moysich KB, Olson SH, Pearce CL, Pike MC, Rothstein JH, Sellers TA, Sieh W, Stram D, Thompson PJ, Vierkant RA, Wicklund KG, Wu AH, Ziogas A, Tworoger SS, Schildkraut JM; , on behalf of the Ovarian Cancer Association Consortium..

Am J Epidemiol. 2016 Oct 15;184(8):579-589.

PMID:
27698005
2.

Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.

Menkiszak J, Chudecka-Głaz A, Gronwald J, Cymbaluk-Płoska A, Celewicz A, Świniarska M, Wężowska M, Bedner R, Zielińska D, Tarnowska P, Jakubowicz J, Kojs Z.

J Ovarian Res. 2016 Feb 29;9:11. doi: 10.1186/s13048-016-0220-4.

3.

Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.

Blyuss O, Gentry-Maharaj A, Fourkala EO, Ryan A, Zaikin A, Menon U, Jacobs I, Timms JF.

Biomed Res Int. 2015;2015:681416. doi: 10.1155/2015/681416.

4.

Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?

Chudecka-Głaz A, Cymbaluk-Płoska A, Jastrzębska J, Menkiszak J.

Tumour Biol. 2016 Jul;37(7):8879-87. doi: 10.1007/s13277-015-4733-z.

5.

Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.

Cho HY, Park SH, Park YH, Kim HB, Kang JB, Hong SH, Kyung MS.

J Korean Med Sci. 2015 Dec;30(12):1777-83. doi: 10.3346/jkms.2015.30.12.1777.

6.

Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.

Urban N, Hawley S, Janes H, Karlan BY, Berg CD, Drescher CW, Manson JE, Palomares MR, Daly MB, Wactawski-Wende J, O'Sullivan MJ, Thorpe J, Robinson RD, Lane D, Li CI, Anderson GL.

Gynecol Oncol. 2015 Nov;139(2):253-60. doi: 10.1016/j.ygyno.2015.08.024.

7.

Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.

Zhang Y, Qiao C, Li L, Zhao X, Li Y.

Afr Health Sci. 2014 Dec;14(4):913-8. doi: 10.4314/ahs.v14i4.20.

8.

Expression level of serum human epididymis 4 and its prognostic significance in human non-small cell lung cancer.

Jiang Y, Wang C, Lv B, Ma G, Wang L.

Int J Clin Exp Med. 2014 Dec 15;7(12):5568-72.

9.

Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal masses.

Farzaneh F, Honarvar Z, Yaraghi M, Yaseri M, Arab M, Hosseini M, Ashrafgangoi T.

Iran Red Crescent Med J. 2014 Jun;16(6):e17185. doi: 10.5812/ircmj.17185.

10.
11.

Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample.

Brain KE, Smits S, Simon AE, Forbes LJ, Roberts C, Robbé IJ, Steward J, White C, Neal RD, Hanson J; ICBP Module 2 Working Group..

BMC Cancer. 2014 Mar 10;14:171. doi: 10.1186/1471-2407-14-171.

12.

Value of symptom-triggered diagnostic evaluation for ovarian cancer.

Andersen MR, Lowe KA, Goff BA.

Obstet Gynecol. 2014 Jan;123(1):73-9. doi: 10.1097/AOG.0000000000000051.

13.

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.

Pitta Dda R, Sarian LO, Barreta A, Campos EA, Andrade LL, Fachini AM, Campbell LM, Derchain S.

BMC Cancer. 2013 Sep 18;13:423. doi: 10.1186/1471-2407-13-423.

14.
15.

The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.

Simmons AR, Baggerly K, Bast RC Jr.

Oncology (Williston Park). 2013 Jun;27(6):548-56. Review.

16.

Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis.

Yang Z, Wei C, Luo Z, Li L.

Onco Targets Ther. 2013 Jul 23;6:957-66. doi: 10.2147/OTT.S45681. Erratum in: Onco Targets Ther. 2014;7:135.

17.

The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors.

Lawicki S, Będkowska GE, Gacuta-Szumarska E, Szmitkowski M.

J Ovarian Res. 2013 Jul 2;6(1):45. doi: 10.1186/1757-2215-6-45.

18.

Biomarker testing for ovarian cancer: clinical utility of multiplex assays.

Nolen BM, Lokshin AE.

Mol Diagn Ther. 2013 Jun;17(3):139-46. doi: 10.1007/s40291-013-0027-6. Review.

19.

Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.

Urban N, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, Paley P, Drescher CW.

Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2087-94. doi: 10.1158/1055-9965.EPI-12-0616.

20.

High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer.

Kalapotharakos G, Asciutto C, Henic E, Casslén B, Borgfeldt C.

J Ovarian Res. 2012 Aug 21;5(1):20. doi: 10.1186/1757-2215-5-20.

Items per page

Supplemental Content

Support Center